



AMERICAN
COLLEGE of
CARDIOLOGY®

TRILUMINATE PIVOTAL

Transcatheter Repair For Patients With
Tricuspid Regurgitation

Multicenter, International, Randomized Trial

OBJECTIVE: To evaluate the safety and effectiveness of a percutaneous transcatheter edge-to-edge repair (TEER) device in patients with severe tricuspid regurgitation (TR).

350
PATIENTS



TEER
(N=175)

INCLUSION CRITERIA: Severe symptomatic TR, stable medical or device therapy for heart failure (HF) ≥ 30 days, NYHA class II-IV HF, intermediate or greater risk of morbidity/mortality with tricuspid valve surgery

VS.



MEDICAL THERAPY
(N=175)

PRIMARY ENDPOINT

THE COMPOSITE PRIMARY OUTCOME OF ALL-CAUSE MORTALITY OR TRICUSPID VALVE SURGERY, HF HOSPITALIZATION AND IMPROVEMENT ≥ 15 POINTS IN KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE AT 12 MONTHS WAS 11,348 VS. 7,643 WINS (WIN RATIO 1.48, P=0.02).

CONCLUSION

Tricuspid TEER was a safe intervention to reduce severe TR and improve outcomes, primarily quality of life, compared to medical therapy alone.

Sorajja P, Whisenant B, Hamid N, et al., on behalf of the TRILUMINATE Pivotal Investigators. Transcatheter Repair for Patients with Tricuspid Regurgitation. *N Engl J Med* 2023;Mar 4:[Epub ahead of print].

Developed and reviewed by Amit Saha, MD; Anthony A. Bavry, MD, MPH, FACC; and Deepak L. Bhatt, MD, MPH, FACC.